XORTX Therapeutics (XRTX)
Develops oral oxypurinol therapies for gout and kidney disease.
XORTX Announces Termination and Postponement of Investor Relations Program
CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “IR Agreement”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable in advance. The fee was fully earned upon receipt and non-refundable. Under the mutual agreement of the parties, the arrangement has been rescinded, all services contemplated under the agreement have been discontinued and the funds previously paid to IR Agency LLC in connection with the agreement were returned to the Company on August 14, 2026. The original arrangement was disclosed in connection with the Company's US$5 million public offering completed on May 19, 2026. A portion of the offering proceeds, in an amount equal to US$2.5 million, had been allocated to IR Agency LLC for marketing and advertising services.
XORTX Announces Director Resignation
CALGARY, Alberta, July 31, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that Anthony Giovinazzo is stepping down from the board of directors for personal reasons and to pursue other interests. Dr. Allen Davidoff, co-CEO of XORTX, stated, “XORTX management and the board of directors extends our heartfelt appreciation for Mr.
XORTX Appoints New Director
CALGARY, Alberta, July 29, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the appointment of Depesh Narotam to the board of directors as an independent director. Depesh Narotam has been in the financial services industry for over 20 years.
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs. The Company's current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead program for gout.
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange (“TSXV”). The Company will provide additional information on timing for the completion of the delisting of its common shares in a separate press release.
XORTX Announces Closing of US$5 Million Public Offering
CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares ("Common Shares") or common shares equivalents in lieu thereof (“Pre-Funded Warrants”) at a purchase price of US$1.88 (the “Offering”).
E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the exclusive placement agent in connection with a $5 million public offering for XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease.
XORTX Announces US$5 Million Public Offering
CALGARY, Alberta, May 14, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces the pricing of a public offering of 2,659,574 common shares (“Common Shares”) or common shares equivalents in lieu thereof (“Pre-Funded Warrants”) at an offering price of US$1.88 for gross proceeds of US$5 million, prior to deducting placement agent's fees and other offering expenses (the “Offering”). The Pre-Funded Warrants have an exercise price of US$0.0001 per share, will be immediately exercisable, and will terminate once exercised in full.
XORTX Therapeutics Inc. (NASDAQ:XRTX) Short Interest Update
XORTX Therapeutics Inc. (NASDAQ: XRTX - Get Free Report) saw a large increase in short interest during the month of April. As of April 15th, there was short interest totaling 44,502 shares, an increase of 129.0% from the March 31st total of 19,435 shares. Approximately 3.4% of the shares of the stock are sold short. Based
XORTX Confirms Effective Date of Share Consolidation
CALGARY, Alberta, April 01, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, further to its news release of March 26, 2026, the implementation of its share consolidation on the basis of one (1) new common share for every five (5) old common shares (the “Consolidation”) has received all required approvals of the TSX Venture Exchange and Nasdaq Stock Exchange and will occur on April 6, 2026.
XORTX Announces Results of Annual and Special Meeting of Shareholders
CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held Tuesday, March 24, 2026.
XORTX Announces Change of Effective Date of Share Consolidation
CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, further to its news release of March 25, 2026, the Company has delayed the implementation of its share consolidation on the basis of one (1) new common share for every five (5) old common shares (the “Consolidation”) from March 27, 2026 to April 6, 2026, and remains subject to the receipt of all required approvals of the TSX Venture Exchange and Nasdaq Stock Exchange.
XORTX Announces Share Consolidation
CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company's board of directors has approved consolidating (the “Consolidation”) its common shares (“Shares”) on the basis of one post-consolidation Share for every five pre-consolidation Shares, effective March 27, 2025 (the “Effective Date”). The Company will not undergo a name change in connection with the Consolidation.
XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation
CALGARY, Alberta, March 13, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce that independent proxy advisory firms, including Institutional Shareholder Services (“ISS”) have recommended shareholders vote “FOR” on the share consolidation at the upcoming shareholder meeting scheduled for March 24, 2026.
XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update
CALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, highlights recent peer-reviewed, independent, published research reports that expand current knowledge that genetic factors are linked to the over-expression of xanthine oxidase ("XO"), high chronic uric acid concentrations in the blood and gout.
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
CALGARY, Alberta, Oct. 21, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has entered into a securities purchase agreement with an institutional investor for the purchase and sale of 1,746,631 common shares (or common share equivalents in lieu thereof) in a registered direct offering (the “Offering”) at a purchase price of US$0.63 per common share.
XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
Acquisition includes novel new chemical entity VB4-P5 with potential to address significant unmet needs in rare and large-market kidney diseases Acquisition includes novel new chemical entity VB4-P5 with potential to address significant unmet needs in rare and large-market kidney diseases
XORTX Initiates IND Preparation for XORLO™ in Gout Program
Engagement with Allucent supports NDA pathway and advancement of late-stage gout program Engagement with Allucent supports NDA pathway and advancement of late-stage gout program
XORTX Completes USD $114,500 Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Aug. 08, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces the closing of its previously announced non-brokered private placement of units (“Units”), whereby it issued 156,849 Units at a price of US$0.73 per Unit for aggregate gross proceeds of US$114,500 (the “Offering”). Under the Offering, each Unit consisted of one common share in the capital of the Company (“Common Share”) and one common share purchase warrant (“Warrant”).
XORTX Completes Non-Brokered Private Placement of Units
Not For Distribution to United States News Wire Services or for Dissemination in the United States CALGARY, Alberta, July 22, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the closing of its previously announced non-brokered private placement of units (“Units”), whereby it issued 1,267,123 Units at a price of US$0.73 per Unit for aggregate gross proceeds of US$925,000 pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions (the “Offering”). Under the Offering, each Unit consisted of one common share in the capital of the Company (“Common Share”) and one common share purchase warrant (“Warrant”).